Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device

Mohammad Qasaimeh, Yichao C. Wu, Suman Bose, Anoop Menachery, Srikanth Talluri, Gabriel Gonzalez, Mariateresa Fulciniti, Jeffrey M. Karp, Rao H. Prabhala, Rohit Karnik

    Research output: Contribution to journalArticle

    Abstract

    The necessity for bone marrow aspiration and the lack of highly sensitive assays to detect residual disease present challenges for effective management of multiple myeloma (MM), a plasma cell cancer. We show that a microfluidic cell capture based on CD138 antigen, which is highly expressed on plasma cells, permits quantitation of rare circulating plasma cells (CPCs) in blood and subsequent fluorescence-based assays. The microfluidic device is based on a herringbone channel design, and exhibits an estimated cell capture efficiency of ∼40-70%, permitting detection of <10 CPCs/mL using 1-mL sample volumes, which is difficult using existing techniques. In bone marrow samples, the microfluidic-based plasma cell counts exhibited excellent correlation with flow cytometry analysis. In peripheral blood samples, the device detected a baseline of 2-5 CD138 + cells/mL in healthy donor blood, with significantly higher numbers in blood samples of MM patients in remission (20-24 CD138 + cells/mL), and yet higher numbers in MM patients exhibiting disease (45-184 CD138 + cells/mL). Analysis of CPCs isolated using the device was consistent with serum immunoglobulin assays that are commonly used in MM diagnostics. These results indicate the potential of CD138-based microfluidic CPC capture as a useful â € liquid biopsy' that may complement or partially replace bone marrow aspiration.

    Original languageEnglish (US)
    Article number45681
    JournalScientific Reports
    Volume7
    DOIs
    StatePublished - Apr 4 2017

    Fingerprint

    Lab-On-A-Chip Devices
    Plasma Cells
    Multiple Myeloma
    Antibodies
    Microfluidics
    Bone Marrow
    Syndecan-1
    Equipment and Supplies
    Blood Donors
    Immunoglobulins
    Flow Cytometry
    Cell Count
    Fluorescence

    ASJC Scopus subject areas

    • General

    Cite this

    Qasaimeh, M., Wu, Y. C., Bose, S., Menachery, A., Talluri, S., Gonzalez, G., ... Karnik, R. (2017). Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device. Scientific Reports, 7, [45681]. https://doi.org/10.1038/srep45681

    Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device. / Qasaimeh, Mohammad; Wu, Yichao C.; Bose, Suman; Menachery, Anoop; Talluri, Srikanth; Gonzalez, Gabriel; Fulciniti, Mariateresa; Karp, Jeffrey M.; Prabhala, Rao H.; Karnik, Rohit.

    In: Scientific Reports, Vol. 7, 45681, 04.04.2017.

    Research output: Contribution to journalArticle

    Qasaimeh, M, Wu, YC, Bose, S, Menachery, A, Talluri, S, Gonzalez, G, Fulciniti, M, Karp, JM, Prabhala, RH & Karnik, R 2017, 'Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device', Scientific Reports, vol. 7, 45681. https://doi.org/10.1038/srep45681
    Qasaimeh, Mohammad ; Wu, Yichao C. ; Bose, Suman ; Menachery, Anoop ; Talluri, Srikanth ; Gonzalez, Gabriel ; Fulciniti, Mariateresa ; Karp, Jeffrey M. ; Prabhala, Rao H. ; Karnik, Rohit. / Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device. In: Scientific Reports. 2017 ; Vol. 7.
    @article{b96d347b8ee449b4b115ae1b56ede112,
    title = "Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device",
    abstract = "The necessity for bone marrow aspiration and the lack of highly sensitive assays to detect residual disease present challenges for effective management of multiple myeloma (MM), a plasma cell cancer. We show that a microfluidic cell capture based on CD138 antigen, which is highly expressed on plasma cells, permits quantitation of rare circulating plasma cells (CPCs) in blood and subsequent fluorescence-based assays. The microfluidic device is based on a herringbone channel design, and exhibits an estimated cell capture efficiency of ∼40-70{\%}, permitting detection of <10 CPCs/mL using 1-mL sample volumes, which is difficult using existing techniques. In bone marrow samples, the microfluidic-based plasma cell counts exhibited excellent correlation with flow cytometry analysis. In peripheral blood samples, the device detected a baseline of 2-5 CD138 + cells/mL in healthy donor blood, with significantly higher numbers in blood samples of MM patients in remission (20-24 CD138 + cells/mL), and yet higher numbers in MM patients exhibiting disease (45-184 CD138 + cells/mL). Analysis of CPCs isolated using the device was consistent with serum immunoglobulin assays that are commonly used in MM diagnostics. These results indicate the potential of CD138-based microfluidic CPC capture as a useful {\^a} € liquid biopsy' that may complement or partially replace bone marrow aspiration.",
    author = "Mohammad Qasaimeh and Wu, {Yichao C.} and Suman Bose and Anoop Menachery and Srikanth Talluri and Gabriel Gonzalez and Mariateresa Fulciniti and Karp, {Jeffrey M.} and Prabhala, {Rao H.} and Rohit Karnik",
    year = "2017",
    month = "4",
    day = "4",
    doi = "10.1038/srep45681",
    language = "English (US)",
    volume = "7",
    journal = "Scientific Reports",
    issn = "2045-2322",
    publisher = "Nature Publishing Group",

    }

    TY - JOUR

    T1 - Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device

    AU - Qasaimeh, Mohammad

    AU - Wu, Yichao C.

    AU - Bose, Suman

    AU - Menachery, Anoop

    AU - Talluri, Srikanth

    AU - Gonzalez, Gabriel

    AU - Fulciniti, Mariateresa

    AU - Karp, Jeffrey M.

    AU - Prabhala, Rao H.

    AU - Karnik, Rohit

    PY - 2017/4/4

    Y1 - 2017/4/4

    N2 - The necessity for bone marrow aspiration and the lack of highly sensitive assays to detect residual disease present challenges for effective management of multiple myeloma (MM), a plasma cell cancer. We show that a microfluidic cell capture based on CD138 antigen, which is highly expressed on plasma cells, permits quantitation of rare circulating plasma cells (CPCs) in blood and subsequent fluorescence-based assays. The microfluidic device is based on a herringbone channel design, and exhibits an estimated cell capture efficiency of ∼40-70%, permitting detection of <10 CPCs/mL using 1-mL sample volumes, which is difficult using existing techniques. In bone marrow samples, the microfluidic-based plasma cell counts exhibited excellent correlation with flow cytometry analysis. In peripheral blood samples, the device detected a baseline of 2-5 CD138 + cells/mL in healthy donor blood, with significantly higher numbers in blood samples of MM patients in remission (20-24 CD138 + cells/mL), and yet higher numbers in MM patients exhibiting disease (45-184 CD138 + cells/mL). Analysis of CPCs isolated using the device was consistent with serum immunoglobulin assays that are commonly used in MM diagnostics. These results indicate the potential of CD138-based microfluidic CPC capture as a useful â € liquid biopsy' that may complement or partially replace bone marrow aspiration.

    AB - The necessity for bone marrow aspiration and the lack of highly sensitive assays to detect residual disease present challenges for effective management of multiple myeloma (MM), a plasma cell cancer. We show that a microfluidic cell capture based on CD138 antigen, which is highly expressed on plasma cells, permits quantitation of rare circulating plasma cells (CPCs) in blood and subsequent fluorescence-based assays. The microfluidic device is based on a herringbone channel design, and exhibits an estimated cell capture efficiency of ∼40-70%, permitting detection of <10 CPCs/mL using 1-mL sample volumes, which is difficult using existing techniques. In bone marrow samples, the microfluidic-based plasma cell counts exhibited excellent correlation with flow cytometry analysis. In peripheral blood samples, the device detected a baseline of 2-5 CD138 + cells/mL in healthy donor blood, with significantly higher numbers in blood samples of MM patients in remission (20-24 CD138 + cells/mL), and yet higher numbers in MM patients exhibiting disease (45-184 CD138 + cells/mL). Analysis of CPCs isolated using the device was consistent with serum immunoglobulin assays that are commonly used in MM diagnostics. These results indicate the potential of CD138-based microfluidic CPC capture as a useful â € liquid biopsy' that may complement or partially replace bone marrow aspiration.

    UR - http://www.scopus.com/inward/record.url?scp=85016930527&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85016930527&partnerID=8YFLogxK

    U2 - 10.1038/srep45681

    DO - 10.1038/srep45681

    M3 - Article

    VL - 7

    JO - Scientific Reports

    JF - Scientific Reports

    SN - 2045-2322

    M1 - 45681

    ER -